Clinical Report: FDA Requests Confirmatory Evidence on Wet AMD Therapy

Overview

The FDA issued a complete response letter for Outlook Therapeutics’ ONS-5010/LYTENAVA in wet age-related macular degeneration, citing the need for confirmatory evidence after the therapy failed a primary efficacy endpoint in the NORSE EIGHT trial. The therapy met its primary endpoint in another trial, NORSE TWO, but the FDA noted that it could not approve the application in its present form.

Background

Wet age-related macular degeneration (AMD) is a leading cause of vision loss in older adults, necessitating effective treatment options. Current management primarily involves intravitreal anti-VEGF injections, such as ranibizumab and aflibercept, with ongoing research to improve efficacy and durability of therapies. The regulatory status of new treatments like ONS-5010/LYTENAVA is critical for expanding therapeutic options in this patient population.

Data Highlights

No numerical data available in the source material.

Key Findings

• The FDA issued a complete response letter for ONS-5010/LYTENAVA, requesting additional confirmatory evidence.
• ONS-5010 met its primary endpoint in the NORSE TWO trial.
• ONS-5010 failed the primary efficacy endpoint in the NORSE EIGHT trial.
• LYTENAVA holds Marketing Authorization in the EU and UK for wet AMD treatment.
• Commercial availability of LYTENAVA began in June 2025 in Germany and the UK.

Clinical Implications

The FDA's request for confirmatory evidence is based on the outcomes of the clinical trials and highlights the ongoing evaluation process for new therapies.

Conclusion

The evaluation of ONS-5010/LYTENAVA is ongoing, and further research and regulatory scrutiny are necessary for advancing care in wet AMD.

Related Resources & Content

1. Outlook Therapeutics, FDA Complete Response Letter, 2025 -- FDA Requests Confirmatory Evidence on Wet AMD Therapy
2. Retinal Physician, Triple Therapy for Wet AMD Shows Impressive Results, 2008 -- Dynamic disease requires complex approach
3. Retinal Physician, Clinical Trials Update, 2009 -- Clinical Trial Update
4. Retinal Physician, Clinical Trial Update November/December 2025, 2025 -- Clinical Trial Update
5. National Eye Institute, Injections to Treat Eye Conditions, 2023 -- Current practice and guidance
6. New England Journal of Medicine, Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration, 2011 -- Major trial and evidence landscape
7. retinal physician — Clinical Trial Update May 2025
8. Injections to Treat Eye Conditions | National Eye Institute
9. Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration | New England Journal of Medicine
10. FDA Complete Response Letter